Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biontech Se ADR
(NQ:
BNTX
)
85.46
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biontech Se ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
Today 6:45 EDT
From
BioNTech SE
Via
GlobeNewswire
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
July 02, 2024
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.
Via
MarketBeat
Topics
ETFs
Exposures
COVID-19
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
June 24, 2024
From
BioNTech SE
Via
GlobeNewswire
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
June 06, 2024
Via
AB Newswire
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
June 06, 2024
Via
AB Newswire
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns
May 30, 2024
Via
AB Newswire
Exposures
COVID-19
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
May 29, 2024
From
BioNTech SE
Via
GlobeNewswire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
Genmab A/S
Via
Business Wire
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
May 21, 2024
From
BioNTech SE
Via
GlobeNewswire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
May 17, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
May 06, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
April 22, 2024
From
BioNTech SE
Via
GlobeNewswire
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
April 07, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
March 20, 2024
From
BioNTech SE
Via
GlobeNewswire
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
March 20, 2024
From
BioNTech SE
Via
GlobeNewswire
BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
March 12, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
March 12, 2024
WHY: NEW YORK, NY - (NewMediaWire) - March 12, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
BNTX DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
March 11, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
BNTX DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
March 11, 2024
WHY: NEW YORK, NY - (NewMediaWire) - March 11, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX)
March 11, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE
March 11, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
March 11, 2024
From
BioNTech SE
Via
GlobeNewswire
BNTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
March 10, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
BNTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
March 10, 2024
WHY: NEW YORK, NY - (NewMediaWire) - March 10, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
BNTX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
March 09, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
BNTX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
March 09, 2024
WHY: NEW YORK, NY - (NewMediaWire) - March 09, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and...
Via
TheNewswire.com
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
BIONTECH DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm
March 08, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.